US EditionPromising vaccine may prevent certain cancers from returning
The ELI-002 2P vaccine induced strong immune responses in 21 of 25 patients, correlating with delayed cancer recurrence and longer survival in high-risk KRAS-mutated cases.
- Researchers from UCLA Health announced results of a phase 1 trial testing the ELI-002 2P cancer vaccine on 25 patients treated for pancreatic and colorectal cancer.
- The trial enrolled high-risk patients with minimal residual disease after surgery, aiming to prevent cancer recurrence driven by KRAS mutations.
- Twenty-One patients generated strong KRAS-specific T-cell responses, with most remaining cancer-free for nearly 20 months and six showing no tumor biomarkers.
- Dr. Zev Wainberg said the vaccine safely trains the immune system and offers a promising off-the-shelf approach for durable immune responses in KRAS-driven cancers.
- The completed phase 2 randomized study, with results due in 2026, could confirm lowered recurrence or death rates and indicate new hope for pancreatic cancer treatment.
18 Articles
18 Articles
Promising vaccine may prevent certain cancers from returning
(NewsNation) — An experimental cancer vaccine has shown promising results in keeping pancreatic and colorectal cancers from coming back. In a clinical trial led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, researchers tested the vaccine on 25 patients who had previously been treated for pancreatic and colorectal cancers. Colorectal cancer is the third most common cancer diagnosed in both men and women …
A new vaccine that stimulates the immunological system to attack one of the most common mutations that cause cancer has been shown promising in the prevention of pancreatic and intestinal tumor recurrence, according to an initial clinical test by researchers at the UCLA Health Jonsson Comprehensive Cancer Center and the Memorial Hospital Sloan Kettering Cancer Center in New York. These cancers are among the most difficult to treat.
The ELI-002 vaccine, developed by immunologist Darrel Irvine and his team from the Massachusetts Institute of Technology (MIT), advances as a promising option in the fight against pancreatic and colon cancer.
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
